Zacks Investment Research cut shares of Orchard Therapeutics (NASDAQ:ORTX) from a hold rating to a sell rating in a research note released on Friday, Zacks.com reports.

According to Zacks, “Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based in London, United Kingdom. “

Separately, ValuEngine upgraded Orchard Therapeutics from a hold rating to a buy rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $23.80.

NASDAQ:ORTX traded down $0.34 during midday trading on Friday, hitting $13.77. 130,100 shares of the company traded hands, compared to its average volume of 143,569. The firm’s fifty day moving average is $13.52 and its 200-day moving average is $16.01. Orchard Therapeutics has a 12-month low of $8.65 and a 12-month high of $21.64. The firm has a market capitalization of $1.20 billion and a P/E ratio of -1.35. The company has a current ratio of 7.89, a quick ratio of 9.18 and a debt-to-equity ratio of 0.07.

Orchard Therapeutics (NASDAQ:ORTX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.20). On average, research analysts expect that Orchard Therapeutics will post -1.84 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its position in Orchard Therapeutics by 99.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,046,558 shares of the company’s stock valued at $56,611,000 after acquiring an additional 2,015,870 shares during the last quarter. Cowen Inc. grew its position in Orchard Therapeutics by 4.4% in the 2nd quarter. Cowen Inc. now owns 3,035,364 shares of the company’s stock valued at $42,465,000 after acquiring an additional 127,737 shares during the last quarter. Vivo Capital LLC grew its position in Orchard Therapeutics by 172.4% in the 2nd quarter. Vivo Capital LLC now owns 1,312,084 shares of the company’s stock valued at $18,356,000 after acquiring an additional 830,475 shares during the last quarter. Putnam Investments LLC grew its position in Orchard Therapeutics by 203.2% in the 2nd quarter. Putnam Investments LLC now owns 1,156,153 shares of the company’s stock valued at $16,175,000 after acquiring an additional 774,853 shares during the last quarter. Finally, Westfield Capital Management Co. LP grew its position in Orchard Therapeutics by 99.8% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,044,336 shares of the company’s stock valued at $14,610,000 after acquiring an additional 521,646 shares during the last quarter. 57.15% of the stock is currently owned by institutional investors.

About Orchard Therapeutics

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

See Also: Real Estate Investment Trust (REIT) ETF

Get a free copy of the Zacks research report on Orchard Therapeutics (ORTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.